Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics

Golay, Josée, Semenzato, Gianpietro, Rambaldi, Alessandro, Foà, Robin, Gaidano, Gianluca, Gamba, Enrica, Pane, Fabrizio, Pinto, Antonello +3 more·2013·mAbs
DOI 10.4161/mabs.26008

Cited by (146)

Items 101–146 of 146

  1. Desensitization and management of allograft rejection
    Lorenzo Zaffiri · 2021 · Current Opinion in Organ Transplantation
  2. Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion
    Marek Borský, Viera Hrabčáková, Jitka Novotná, Yvona Brychtová, Michael Doubek, Anna Panovská, Petr Müller, Jiřı́ Mayer, Martin Trbušek, Marek Mráz · 2021 · Leukemia Research
  3. Assessment of cell death mechanisms triggered by 177 Lu-anti-CD20 in lymphoma cells
    Erika Patricia Azorin‐Vega, Eva L. Rojas-Calderón, B. Martínez-Ventura, J. Ramos-Bernal, Luis Serrano-Espinoza, Nallely Jiménez‐Mancilla, David Ordaz‐Rosado, Guillermina Ferro‐Flores · 2017 · Applied Radiation and Isotopes
  4. Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome
    Shu Liu, Zhao Wang, Rongxin Chen, Xueding Wang, Xiaojie Fang, Zhuojia Chen, Shaoxing Guan, Tao Liu, Tongyu Lin, Min Huang et al. · 2022 · Frontiers in Pharmacology
  5. Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India
    Ankit Patel, Niraj Bhatt, S. S. Prakash, Ghanashyam Biswas, Rajnish Vasant Nagarkar, Bodhisatta Roy, Priyanka Samal, Narendra Agrawal, Sushil Meshram, Ashish Kaushal et al. · 2023 · Cancer Chemotherapy and Pharmacology
  6. KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas
    Chiara Tarantelli, Filippo Spriano, Elisa Civanelli, Luca Aresu, Giorgia Risi, Eleonora Cannas, Omar Kayali, Luciano Cascione, Alberto J. Arribas, Anastasios Stathis et al. · 2025 · Cancers
  7. Pharmacokinetic profiling of rituximab in glomerular diseases: key determinants and implications for personalized therapy
    George Zhang, Qijun Wan, Yuan Cheng · 2026 · Frontiers in Pharmacology
  8. Rituximab beyond oncology: targeting B-cell-mediated immunomodulatory therapy in neurodegenerative and neuropsychiatric disorders
    Trina Saha, Tanya Vats, Sidharth Mehan · 2026 · Immunopharmacology and Immunotoxicology
  9. Clinical development of subcutaneous dosing alternatives to established intravenous formulations for monoclonal antibodies—pharmacokinetic-based bridging approach
    Beate Bittner, Johannes Schmidt · 2022 · Elsevier eBooks
  10. Anti-CD20 Antibody and Calcineurin Inhibitor Combination Therapy Effectively Suppresses Antibody-Mediated Rejection in Murine Orthotopic Lung Transplantation
    Hiroki Matsumoto, Hidemi Suzuki, Takahiro Yamanaka, Taisuke Kaiho, Atsushi Hata, Terunaga Inage, Takamasa Ito, Toshiko Kamata, Kazuhisa Tanaka, Yuichi Sakairi et al. · 2023 · Life
  11. A short review of the pharmacokinetic behavior of biological medicinal agents for the clinical practice
    Sándor Kerpel‐Fronius · 2017 · Microchemical Journal
  12. Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach
    Chiara Tarantelli, David N. Wald, Nicolas Munz, Filippo Spriano, Alessio Bruscaggin, Eleonora Cannas, Luciano Cascione, Eugenio Gaudio, Alberto J. Arribas, Shivaprasad Manjappa et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  13. Predicting human subcutaneous bioavailability of monoclonal antibodies using an open flow microperfusion porcine model
    Gerd Schwagerle, Rodolfo Hernandes Bonan, Mikolaj Milewski, Manuel Sánchez-Félix, Sachin Mittal, Shiven Kapur, Kaoutar Abbou Oucherif, Wen‐Kai Hsiao, Laura Wiltschko, Selma Mautner et al. · 2025 · Journal of Controlled Release
  14. Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report
    Mirco Armenti, Sara Maioli, Chiara Riva, Nicola Currò, Giorgia Moschetti, Mario Salvi, Ilaria Muller · 2025 · Thyroid Research
  15. Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA
    Roberto Dal Pozzolo, Luca Iorio, Federica Davanzo, Elisabetta Zanatta, Luca Iaccarino, Roberta Ramonda, Roberto Gerli, Andrea Doria, Giacomo Cafaro, Roberto Padoan · 2026 · Clinical Reviews in Allergy & Immunology
  16. The pharmacokinetics and its covariates of rituximab in different clinical populations: a systematic review and narrative synthesis
    Zhenyan Bo, Liang Huang, Jiayi Lu, Zhe Chen, Zhimei Jiang, Linan Zeng, Yuhong Tao, Lingli Zhang · 2026 · European Journal of Clinical Pharmacology
  17. Rituximab in the treatment of pemphigus
    Shawn Shetty, A. Razzaque Ahmed · 2016 · Expert Opinion on Orphan Drugs
  18. Rituximab dosing in B cell lymphoma
    2018 · Science Proceedings
  19. 85 Antibody-Mediated Rejection after Lung Transplantation
    Ramsey R. Hachem, J.P. Ritter, Roger D. Yusen, Angela R. Wills, Jennifer Iuppa Melaragno, Derek E. Byers, Thalachallour Mohanakumar, Alexander Patterson, Elbert P. Trulock · 2011 · The Journal of Heart and Lung Transplantation
  20. Antibody-Based Biotherapeutics in Inflammatory Diseases
    Honghui Zhou, Yan Chun Xu, Amarnath Sharma · 2019 · Springer eBooks
  21. Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma
    Nikki Blosser, Jennifer Jupp, Patrick Yau, Douglas Allan Stewart · 2019 · Clinical Pharmacokinetics
  22. Research Progress on Quantification Methods of Drug Concentration of Monoclonal Antibodies
    Linlin Hu, Jinlu Zhang, Hua Shao · 2022 · Current Pharmaceutical Analysis
  23. Role of antibodies in autoimmunity of the central nervous system
    César Cordero Gómez · 2020
  24. PHARMACOKINETICS OF BIO-THERAPEUTICS: Rituximab.
    IJAR, Parbhat Saini. · 2017 · International Journal of Advanced Research
  25. Déterminer la dose à injecter lors des premières études cliniques menées avec un anticorps monoclonal
    Marie Viala, Diégo Tosi · 2019 · médecine/sciences
  26. Is it time to say goodbye to weekly rituximab in ANCA vasculitis?
    Benzeeta Pinto, Aadhaar Dhooria · 2020 · Clinical Rheumatology
  27. Zellbasierte Therapeutika in der pädiatrischen Rheumatologie
    Norbert Wagner, Tilmann Kallinich · 2021 · Springer Reference Medizin
  28. Studies on biological treatment and biomarkers in systemic lupus erythematosus : longterm effects, risk factors and predictors of response
    Francesca Faustini · 2021 · Figshare
  29. Zellbasierte Therapeutika in der pädiatrischen Rheumatologie
    Norbert Wagner, Tilmann Kallinich · 2022 · Springer Reference Medizin
  30. Biosimilars: Shaping the Future of Haematology
    Blair R. Hesp · 2016 · EMJ Hematology
  31. Acute Rejection of the Lung Allograft: Phenotypes and Management
    Brandon Menachem, Sandrine Hanna, Deepika P. Kulkarni, Hakim Azfar Ali · 2023 · OBM Transplantation
  32. Additive and Dose-Dependent Effect of Rituximab on Pediatric Patients’ Outcomes Concurrently Receiving Immunosuppressive Chemotherapy, A Prospective Cohort Study
    Ali Amanati, Hossein Molavi Vardanjani, Seyed Omid Reza Zekavat, Samane Nematolahi, Haleh Bozorgi, Saranaz Jangjoo, Farima Safari, Dena Masoomi Bandari, Mohammad Ebrahim Keliddar Mohammadi · 2024 · Archives of Pediatric Infectious Diseases
  33. Monoclonal Antibodies Against Human Immunodeficiency Virus (HIV): Current Opinion
    Harshini Senthilkumar, Pavithra Dhamodharan, Deborah Eshak, Subathra Devi Chandrasekaran, Mohanapriya Arumugam · 2025 · Springer eBooks
  34. Clinical Observation of Obinutuzumab Combined with Abelmoschus manihot Tablets in the Treatment of Idiopathic Refractory Membranous Nephropathy
    Xu Zhao, Xuejie Chang, Yuejuan Wang, DUQUN CHEN, Manshu Yu, Jing Zhao, Hong Zhu, Yan Mao, Chenxia Juan · 2025 · Research Square
  35. Additional file 1 of A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
    Mark McClure, Seerapani Gopaluni, Wason, James, Robert B. Henderson, André van Maurik, Caroline O. S. Savage, Charles Dickson Pusey, Alan David Salama, Paul Lyons, Lee, Jacinta et al. · 2024 · Figshare
  36. Additional file 3 of A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
    Mark McClure, Seerapani Gopaluni, Wason, James, Robert B. Henderson, André van Maurik, Caroline O. S. Savage, Charles Dickson Pusey, Alan David Salama, Paul Lyons, Lee, Jacinta et al. · 2024 · Figshare
  37. Additional file 4 of A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
    Mark McClure, Seerapani Gopaluni, Wason, James, Robert B. Henderson, André van Maurik, Caroline O. S. Savage, Charles Dickson Pusey, Alan David Salama, Paul Lyons, Lee, Jacinta et al. · 2024 · Figshare
  38. Additional file 1 of Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease
    Diankun Liu, Zhou, Zhanmei, Wang, Mengyi, Nie, Sheng, Li, Jun, Hu, Bianxiang, He, Wenjuan, Wang, Guobao, Ai, Jun · 2021 · Figshare
  39. Additional file 2 of Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease
    Diankun Liu, Zhou, Zhanmei, Wang, Mengyi, Nie, Sheng, Li, Jun, Hu, Bianxiang, He, Wenjuan, Wang, Guobao, Ai, Jun · 2021 · Figshare
  40. Additional file 2 of A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
    Mark McClure, Seerapani Gopaluni, Wason, James, Robert B. Henderson, André van Maurik, Caroline O. S. Savage, Charles Dickson Pusey, Alan David Salama, Paul Lyons, Lee, Jacinta et al. · 2024 · Figshare
  41. Additional file 5 of A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
    Mark McClure, Seerapani Gopaluni, Wason, James, Robert B. Henderson, André van Maurik, Caroline O. S. Savage, Charles Dickson Pusey, Alan David Salama, Paul A Lyons, Lee, Jacinta et al. · 2024 · Figshare
  42. Additional file 6 of A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
    Mark McClure, Seerapani Gopaluni, Wason, James, Robert B. Henderson, André van Maurik, Caroline O. S. Savage, Charles Dickson Pusey, Alan David Salama, Paul Lyons, Lee, Jacinta et al. · 2024 · Figshare
  43. Pharmacist's role in the validation of chemotherapy prescriptions
    Asma Ben Romdhane, Y. Elfidha, Emna Jaoued, Houda Bouattour, Dora Cherif · 2026 · Journal of Oncology Pharmacy Practice
  44. Obinutuzumab treatment for antineutrophil cytoplasmic antibody-associated vasculitis
    Ye Chen, Zhi-ying Li, Xiangyu Han, M H Zhao, Min Chen · 2026 · Frontiers in Immunology
  45. Combined rituximab and magnesium acetyl taurate therapy attenuates neurodegeneration via ERK/c-JNK/P38MAPK signaling modulation in methylmercury-induced amyotrophic lateral sclerosis-like neurotoxicity
    Trina Saha, Sidharth Mehan · 2026 · Naunyn-Schmiedeberg s Archives of Pharmacology
  46. Application of Novel Genotyping Microarray Technologies in Cancer Research
    Ricardo Ramos, Juan Moreno‐Rubio, Enrique Casado, Guillermo Reglero, Ana Ramı́rez de Molina · 2014 · Comprehensive analytical chemistry